New England Journal of Medicine· 2015Q1
Pembrolizumab versus Ipilimumab in Advanced Melanoma
- 5,881citations
- Q1SCImago
- 2015year
Short summary
Pembrolizumab significantly improved progression-free survival (47.3% vs. 26.5% at 6 months) and overall survival (74.1% vs. 58.2% at 12 months) compared to ipilimumab in advanced melanoma patients, with a lower rate of severe adverse events (10.1-13.3% vs. 19.9%).
AI-generated from the title and abstract; the full text is not read.
TakeawaysIn the app
Key pointsIn the app
Ask the paperIn the app
The rest is in the Pofolia app
Takeaways, key points and questions to the paper; new summaries every day for your field. Free.
Sign in on the web to openField: Oncology
OncologyMedicine